EMA Recommends Extension of Indications for Ribociclib to Include Use in Patients with Early Breast Cancer
New indication concerns the treatment of patients with early breast cancer at high risk of recurrence
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1535 results
Extended Lymphadenectomy Does Not Improve DFS or OS Among Patients with Localised Muscle Invasive Bladder Cancer
Findings from the SWOG S1011 study
A Short-Course of Induction Chemotherapy Followed by Chemoradiotherapy Significantly Improves Survival in Patients with Locally Advanced Cervical Cancer
Findings from the INTERLACE study
Nivolumab Plus AVD Prolongs PFS in Adolescents and Adults with Advanced-Stage Classic Hodgkin’s Lymphoma
Findings from the S1826 study
FDA Approves Amivantamab-vmjw with Carboplatin and Pemetrexed for Non-Small Cell Lung Cancer with EGFR Exon 19 Deletions or L858R Mutations
Evidence for efficacy is based on the results from the MARIPOSA-2 study
FDA Approves Ribociclib with an Aromatase Inhibitor and Ribociclib and Letrozole Co-pack for Early High-Risk Breast Cancer
Evidence for efficacy of ribociclib with a non-steroidal aromatase inhibitor is based on the results from the NATALEE study
Cabozantinib Improves PFS in Patients with Previously Treated, Progressive Advanced Extrapancreatic or Pancreatic Neuroendocrine Tumours
Findings from the CABINET study
Women Diagnosed with Early Breast Cancer Since 2000 Have About a Fifth Lower Rate of Distant Recurrence Than Those Diagnosed in the 1990s
Findings from a pooled analysis of randomised controlled trial data
Adding Pembrolizumab to Trastuzumab and Chemotherapy Prolongs OS in First-Line Treatment for Unresectable or Metastatic HER2-positive Gastric/GEJ Adenocarcinoma
Results of the final analysis of overall survival in the KEYNOTE-811 study
FDA Approves Isatuximab-irfc with Bortezomib, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple Myeloma
Evidence for efficacy is based on the results from the IMROZ study
EMA Recommends Granting a Marketing Authorisation for Serplulimab
It is intended in combination with carboplatin and etoposide for the first-line treatment of adult patients with ES-SCLC
Targeted Therapy, Driven by Comprehensive Genomic Profiling and Molecular Tumour Board, Improves Outcomes In Pretreated Patients with Metastatic Cancer
Findings from the ROME study